Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study

Osteoporosis International

Volumn 26, Issue 1, 2015, Pages 361-372

  Silverman, S L ^a   Siris, E ^b   Kendler, D L ^c   Belazi, D ^d   Brown, J P ^e   Gold, D T ^f   Lewiecki, E M ^g   Papaioannou, A ^h   Simonelli, C ⁱ   Ferreira, I ^j   Balasubramanian, A ^k   Dakin, P ^k   Ho, P ^k   Siddhanti, S ^k   Stolshek, B ^k   Recknor, C ^l  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b Department of Medicine   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d AlchemiPharma LLC   (United States)

^e LAVAL UNIVERSITY   (Canada)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^h MCMASTER UNIVERSITY   (Canada)

ⁱ Health East Osteoporosis Care   (United States)

^j AMGEN LTD   (United Kingdom)

^k AMGEN INC   (United States)

^l United Osteoporosis Centers   (United States)

more..

Author keywords

Adherence; Compliance; Denosumab; Observational study; Osteoporosis; Persistence

Indexed keywords

DENOSUMAB; BONE DENSITY CONSERVATION AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANADA; CHRONIC DIARRHEA; CHRONIC KIDNEY FAILURE; CHRONIC PANCREATITIS; CLOSTRIDIUM DIFFICILE INFECTION; DEPRESSION; DIVORCED PERSON; DRUG HYPERSENSITIVITY; ECZEMA; FEMALE; FEMALE PHYSICIAN; FEMUR FRACTURE; FRAGILITY FRACTURE; HAND INFECTION; HIP FRACTURE; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; LUMBAR SPINE; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MEDICATION COMPLIANCE; MENTAL DISEASE; MULTICENTER STUDY; NECROTIZING FASCIITIS; OBSERVATIONAL STUDY; OPEN STUDY; PATIENT COMPLIANCE; PNEUMONIA; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESIDENTIAL AREA; SEPARATED PERSON; UNITED STATES; WIDOWED PERSON; BONE DENSITY; CLINICAL TRIAL; COMPLICATION; DRUG ADMINISTRATION; DRUG EFFECTS; FEMORAL NECK; LUMBAR VERTEBRA; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PATHOPHYSIOLOGY; STATISTICS AND NUMERICAL DATA; SUBCUTANEOUS DRUG ADMINISTRATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CANADA; DENOSUMAB; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEMUR NECK; HUMANS; INJECTIONS, SUBCUTANEOUS; LUMBAR VERTEBRAE; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PROSPECTIVE STUDIES; UNITED STATES;

EID: 84922071023     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-014-2871-6     Document Type: Article

References (40)

1. NIH Consensus Development Panel on Osteoporosis Prevention D, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795
2. European Foundation for Osteoporosis and Bone Disease, National Osteoporosis Foundation of the USA (1997) Who are candidates for prevention and treatment for osteoporosis? Osteoporos Int 7:1–6
3. Bliuc D, Nguyen ND, Nguyen TV, Eisman JA, Center JR (2013) Compound risk of high mortality following osteoporotic fracture and re-fracture in elderly women and men. J Bone Miner Res 28:2317–2324
4. Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767
5. Jacques RM, Boonen S, Cosman F, Reid IR, Bauer DC, Black DM, Eastell R (2012) Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27:1627–1634
6. Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733
7. Nguyen ND, Ahlborg HG, Center JR, Eisman JA, Nguyen TV (2007) Residual lifetime risk of fractures in women and men. J Bone Miner Res 22:781–788
8. Melton LJ 3rd, Achenbach SJ, Atkinson EJ, Therneau TM, Amin S (2013) Long-term mortality following fractures at different skeletal sites: a population-based cohort study. Osteoporos Int 24:1689–1696
9. U.S. Department of Health and Human Services (2004) Bone health and osteoporosis: A report of the surgeon general. U.S. Department of Health and Human Services. http://www.surgeongeneral.gov/library/reports/bonehealth/
10. Levis S, Theodore G (2012) Summary of AHRQ’s comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report. J Manag Care Pharm 18:S1–S15, discussion S13
11. National Osteoporosis Foundation (2013) Clinician’s guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation. http://nof.org/hcp/clinicians-guide. Accessed 25 Aug, 2013
12. Halpern R, Becker L, Iqbal SU, Kazis LE, Macarios D, Badamgarav E (2011) The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis. J Manag Care Pharm 17:25–39
13. Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E (2011) A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health 14:571–581
14. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022
15. Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122:S3–S13
16. Siris ES, Pasquale MK, Wang Y, Watts NB (2011) Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001–2008. J Bone Miner Res 26:3–11
17. Wade SW, Curtis JR, Yu J, White J, Stolshek BS, Merinar C, Balasubramanian A, Kallich JD, Adams JL, Viswanathan HN (2012) Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan. Bone 50:870–875
18. Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922–928
19. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK (2008) Medication compliance and persistence: terminology and definitions. Value Health 11:44–47
20. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82:1493–1501
21. Arden NK, Earl S, Fisher DJ, Cooper C, Carruthers S, Goater M (2006) Persistence with teriparatide in patients with osteoporosis: the UK experience. Osteoporos Int 17:1626–1629
22. Gold DT, Weinstein DL, Pohl G, Krohn KD, Chen Y, Meadows ES (2011) Factors associated with persistence with teriparatide therapy: results from the DANCE observational study. J Osteoporos 2011:314970
23. Lee YK, Nho JH, Ha YC, Koo KH (2012) Persistence with intravenous zoledronate in elderly patients with osteoporosis. Osteoporos Int 23:2329–2333
24. Curtis JR, Yun H, Matthews R, Saag KG, Delzell E (2012) Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population. Arthritis Care Res (Hoboken) 64:1054–1060
25. Amgen Canada Inc. Prolia® (denosumab) solution for injection. Product monograph. September 5, 2013. http://www.amgen.ca/Prolia_PM.pdf. Accessed 1 Dec 2013
26. Amgen Inc. Prolia® (denosumab) injection. U.S. full prescribing information, July 2013. http://pi.amgen.com/united_states/prolia/prolia_pi.pdf. Accessed 1 Dec 2013
27. Kendler DL, McClung MR, Freemantle N et al (2011) Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int 22:1725–1735
28. Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S, Borenstein J, Kendler DL, Investigators D (2012) Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23:317–326
29. Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG (2010) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 25:72–81
30. Brown JP, Prince RL, Deal C et al (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153–161
31. Wolfe F, Michaud K, Li T, Katz RS (2010) Chronic conditions and health problems in rheumatic diseases: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, systemic lupus erythematosus, and fibromyalgia. J Rheumatol 37:305–315
32. Costs in the coverage gap. Center for Medicare and Medicaid Services. http://www.medicare.gov/part-d/costs/coverage-gap/part-d-coverage-gap.html. Accessed 2 Nov 2013
33. Ware JE Jr, Kosinksi M, Turner-Bowker DM, Ganedek B (2002) How to score version 2 of the SF-12 health survey. QualyMetric, Lincoln
34. Gold DT, Horne R, Coon CD, Price MA, Borenstein J, Varon SF, Satram-Hoang S, Macarios D (2011) Development, reliability, and validity of a new Preference and Satisfaction Questionnaire. Value Health 14:1109–1116
35. Horne R, Weinman J (1999) Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 47:555–567
36. Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972–980
37. Kanis JA, World Health Organization Scientific Group (2007) Assessment of osteoporosis at the primary care health level. Technical Report. WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK
38. Schousboe JT (2013) Adherence with medications used to treat osteoporosis: behavioral insights. Curr Osteoporos Rep 11:21–29
39. Barrett-Connor E, Wade SW, Do TP, Satram-Hoang S, Stewart R, Gao G, Macarios D (2012) Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US. Osteoporos Int 23:733–741
40. Kendler DL, Macarios D, Lillestol MJ, Moffett A, Satram-Hoang S, Huang J, Kaur P, Tang ET, Wagman RB, Horne R (2014) Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study. Menopause 21:25–32